Rockson SG. Update on the biology and treatment of lymphedema. Curr Treat Options Cardiovasc Med. 2012;14:184–92.
Shih YC, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27:2007–14.
Basta MN, et al. Complicated breast cancer-related lymphedema: evaluating health care resource utilization and associated costs of management. Am J Surg. 2016;211:133–41.
Boyages J, et al. Worse and worse off: the impact of lymphedema on work and career after breast cancer. SpringerPlus. 2016;5:657.
Ververs JM, et al. Risk, severity, and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer. 2001;37:991–9.
Shaitelman SF, et al. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin. 2015;65:55–81.
The diagnosis and treatment of peripheral lymphedema: 2016 consensus document of the International Society of Lymphology. Lymphology. 2016;49:170–84.
Armer JM, et al. Best Practice Guidelines in Assessment, Risk Reduction, Management, and Surveillance for Post-Breast Cancer Lymphedema. Curr Breast Cancer Rep. 2013;5:134–44.
Ostby PL, et al. Surveillance recommendations in reducing risk of and optimally managing breast cancer-related lymphedema. J Person Med. 2014;4:424–47.
Perdomo M, Levenhagen K, Ryans K. Breast Cancer EDGE Task Force Outcomes: Assessment measures of secondary lymphedema in breast cancer survivors. Rehabil Oncol. 2014;32:22–35.
NLNMA, C. Supplement to the NLN position breast cancer screening: screening and early detection of breast cancer-related lymphedema. The Imperative. National Lymphedema Network, 2012.
Commitee, NLNMA. Supplement to the NLN position breast cancer screening: screening and early detection of breast cancer -related lymphedema. The Imperative, 2012, National Lymphedema Network.
Armer JM. The problem of post-breast cancer lymphedema: impact and measurement issues. Cancer Invest. 2005;23:76–83.
Olszewski WL (1991) Volumetry of limbs, in Pathophysiology, Diagnosis, and Treatment. CRC Press, Boston pp. 444–51.
Gerber LH. A review of measures of lymphedema. Cancer. 1998;83(12 Suppl):2803–14.
Armer JM, Stewart BR. Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months. Lymphology. 2010;43:118–27.
Taylor R, et al. Reliability and validity of arm volume measurements for assessment of lymphedema. Phys Ther. 2006;86:205–14.
Stout Gergich NL, et al. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer. 2008;112:2809–19.
Johansson K, Branje E. Arm lymphoedema in a cohort of breast cancer survivors 10 years after diagnosis. Acta Oncol. 2010;49:166–73.
Bar Ad V, et al. Time course of mild arm lymphedema after breast conservation treatment for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2010;76:85–90.
Torres Lacomba M, et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ. 2010;340:b5396.
Lahtinen T, et al. Experimental and analytical comparisons of tissue dielectric constant (TDC) and bioimpedance spectroscopy (BIS) in assessment of early arm lymphedema in breast cancer patients after axillary surgery and radiotherapy. Lymphatic Res Biol. 2015;13:176–85.
Stout NL, et al. Breast cancer-related lymphedema: comparing direct costs of a prospective surveillance model and a traditional model of care. Phys Ther. 2012;92:152–63.
C, S. Multifrequency bioimpedance in the early detection of lymphoedema after axillary surgery: an observational cohort study, 2015. Retrieved 16 June 2017 http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN48880939.
Ridner S. A randomized trial evaluating bioimpedance spectroscopy versus tape measurement in the prevention of lymphedema following locoregional treatment for breast cancer, 2014 Retrieved 16 June 2016 https://clinicaltrials.gov/ct2/show/NCT02167659.
Kilbreath SL, et al. Transient swelling versus lymphoedema in the first year following surgery for breast cancer. Support Care Cancer. 2013;21:2207–15.
Laidley A, Anglin B. The impact of L-Dex((R)) measurements in assessing breast cancer-related lymphedema as part of routine clinical practice. Frontiers Oncol. 2016;6:192.
Specht MC, et al. Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression? Breast Cancer Res Treat. 2013;140:485–94.
National Lymphedema Network, July 2012. Retrieved 4 March 2017 www.lymphnet.org.
Armer JM, et al. Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res. 2003;52:370–9.
Teo I, et al. Examining pain, body image, and depressive symptoms in patients with lymphedema secondary to breast cancer. Psycho-oncology. 2015;24:1377–83.
Sackey H, et al. Self-perceived, but not objective lymphoedema is associated with decreased long-term health-related quality of life after breast cancer surgery. Eur J Surg Oncol. 2015;41:577–84.
Bulley C, et al. Comparison of breast cancer-related lymphedema (upper limb swelling) prevalence estimated using objective and subjective criteria and relationship with quality of life. BioMed Res Int. 2013;2013:807569.
Radina E, et al. Self-reported management of breast cancer-related lymphoedema. J Lymphoedema. 2007;2:12–21.
Ridner SH, Dietrich MS, Kidd N. Breast cancer treatment-related lymphedema self-care: education, practices, symptoms, and quality of life. Support Care Cancer. 2011;19:631–7.
Hayes SC, et al. Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer. 2012;118(8 Suppl):2237–49.
Pusic AL, et al. Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes. J Cancer Survivorship Res Pract. 2013;7:83–92.
Brach M, et al. ICF core sets for breast cancer. J Rehabil Med. 2004; 36(44 Suppl):121–127.
Devoogdt N, et al. Lymphoedema functioning, disability, and health questionnaire (Lymph-ICF): reliability and validity. Phys Ther. 2011;91:944–57.
Ridner SH, Dietrich MS. Development and validation of the lymphedema symptom and intensity survey arm. Support Care Cancer. 2015;23:3103–12.
Bulley C, et al. A morbidity screening tool for identifying fatigue, pain, upper limb dysfunction, and lymphedema after breast cancer treatment: a validity study. Eur J Oncol Nurs. 2014;18:218–27.
Fu MR, et al. Symptom report in detecting breast cancer-related lymphedema. Breast Cancer. 2015;7:345–52.
National Comprehensive Cancer Network (NCCN) Guideline Version 2.2016, 2016. Retrieved 23 January 2017 at http://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf .
Blaney JM, et al. Prospective surveillance of breast cancer-related lymphoedema in the first-year post-surgery: feasibility and comparison of screening measures. Support Care Cancer. 2015;23:1549–59.
Czerniec SA, et al. Assessment of breast cancer-related arm lymphedema: comparison of physical measurement methods and self-report. Cancer Invest. 2010;28:54–62.
Gartner R, et al. Self-reported arm-lymphedema and functional impairment after breast cancer treatment: a nationwide study of prevalence and associated factors. Breast. 2010;19:506–15.
Coster S, Poole K, Fallowfield LJ. The validation of a quality-of-life scale to assess the impact of arm morbidity in breast cancer patients postoperatively. Breast Cancer Res Treat. 2001;68:273–82.
Keeley V, C.S., Locke J, Viegas D. A quality-of-life measure for limb lymphedema (LYMQOL). J Lymphoedem. 2010;5:26–37.
Weiss J, Daniel T. Validation of the Lymphedema Life Impact Scale (Llis): a condition-specific measurement tool for persons with lymphedema. Lymphology. 2015;48:128–38.
Ozcinar B, et al. Breast cancer-related lymphedema in patients with different locoregional treatments. Breast. 2012;21:361–5.
Nesvold IL, et al. Arm and shoulder morbidity in breast cancer patients after breast-conserving therapy versus mastectomy. Acta Oncol. 2008;47:835–42.
Ashikaga T, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102:111–8.
Wernicke AG, et al. A 10-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance. Breast Cancer Res. Treat. 2011;125:893–902.
Swaroop MN, et al. Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Res Treat. 2015;151:393–403.
Viera RA, de Souza JL, et al. Risk factors for arm lymphedema in a cohort of breast cancer patients followed for 10 years. Breast Cancer Basel. 2016;11:45–50.
Vicini F, et al. Bioelectrical impedance for detecting and monitoring patients for the development of upper limb lymphedema in the clinic. Clin Breast Cancer. 2012;12:133–7.
Coen JJ, et al. Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2003;55:1209–15.
Hayes SB, et al. Does axillary boost increase lymphedema compared with supraclavicular radiation alone after breast conservation? Int J Radiat Oncol Biol Phys. 2008;72:1449–55.
Kim M, et al. Identification of prognostic risk factors for transient and persistent lymphedema after multimodal treatment for breast cancer. Cancer Res Treat. 2016;48:1330–7.
Kilbreath SL, et al. Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast. 2016;28:29–36.
Donker M, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 noninferiority trial. Lancet Oncol. 2014;15:1303–10.
Cariati M, et al. Adjuvant taxanes and the development of breast cancer-related arm lymphoedema. Br J Surg. 2015;102:1071–8.
Kwan ML, et al. Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study. Arch Surg. 2010;145:1055–63.
Norman SA, et al. Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiol Biomarkers Prev. 2010;19:2734–46.
Wetzig N, et al, Sentinel-lymph-node-based management or routine axillary clearance? Five-year outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: assessment and incidence of true lymphedema. Ann Surg Oncol. 2017;24:1064–70.
Rebegea L, et al. The incidence and risk factors for occurrence of arm lymphedema after treatment of breast cancer. Chirurgia. 2015;110:33–7.
Ridner SH, Dietrich MS. Self-reported comorbid conditions and medication usage in breast cancer survivors with and without lymphedema. Oncol Nurs Forum. 2008;35:57–63.
Deutsch M, et al. The incidence of arm edema in women with breast cancer randomized on the National Surgical Adjuvant Breast and Bowel Project study B-04 to radical mastectomy versus total mastectomy and radiotherapy versus total mastectomy alone. Int J Radiat Oncol Biol Phys. 2008;70:1020–4.
Fu MR. Breast cancer-related lymphedema: symptoms, diagnosis, risk reduction, and management. World J Clin Oncol. 2014;5:241–7.
McLaughlin SA, et al. Trends in risk reduction practices for the prevention of lymphedema in the first 12 months after breast cancer surgery. J Am Coll Surg. 2012; 216:380–389.
Shah C, et al. The impact of early detection and intervention of breast cancer-related lymphedema: a systematic review. Cancer Med. 2016;5:1154–62.
DiSipio T, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14:500–15.
Helyer LK, et al. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. Breast J. 2010;16:48–54.
Boccardo FM, et al. Prospective evaluation of a prevention protocol for lymphedema following surgery for breast cancer. Lymphology. 2009;42:1–9.
Norman SA, et al. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009;27:390–7.
Ugur S, et al. Risk factors of breast cancer-related lymphedema. Lymphat Res Biol. 2013;11:72–5.
Lu SR, et al. Role of physiotherapy and patient education in lymphedema control following breast cancer surgery. Therapeut Clin Risk Manage. 2015;11:319–27.
Basen-Enquist K, T.C., Rosenblum C, Smith MA, Shinn EH, Greisinger A. Randomized pilot test of a lifestyle physical activity intervention for breast cancer survivors. Patient Educ Couns. 2016;64:225–34.
Szuba A, et al. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J. 2002;16:1985–7.
Yoon YS, et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest. 2003;111:717–25.
Jin DP, et al. Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: immunohistochemical and molecular characterization. Lymphat Res Biol. 2009;7:47–57.
Tammela T, et al. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med. 2007;13:1458–66.
Norrmen C, et al. Biological basis of therapeutic lymphangiogenesis. Circulation. 2011;123:1335–51.
Saaristo A, et al. Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB J. 2004;18:1707–9.
Goldman J, et al. Overexpression of VEGF-C causes transient lymphatic hyperplasia but not increased lymphangiogenesis in regenerating skin. Circ Res. 2005;96:1193–9.
Qi S, Pan J. Cell-based therapy for therapeutic lymphangiogenesis. Stem Cells Develop. 2015;24:271–83.
Yan A, et al. Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-beta1 inhibition. Future Oncol. 2011;7:1457–73.
Shimizu Y, Shibata S.R, Shintani S, Ishii M, Murohara T. Therapeutic lymphangiogenesis with implantation of adipose-derived regenerative cells. J Am Heart Assoc. 2012; 1:e000877.
Ackermann M, Senaldi C, Kalbermatten D, Konerding M, Raffoul W, Erba P, Impact of platelet rich plasma and adipose stem cells on lymphangiogenesis in a murine tail lymphedema model. Microvasc Res. 2015;102:78–85.
Chen HC, et al. Lymph node transfer for the treatment of obstructive lymphoedema in the canine model. Br J Plast Surg. 1990;43:578–86.
Becker C, et al. Postmastectomy lymphedema: long-term results following microsurgical lymph node transplantation. Ann Surg. 2006;243:313–5.
Lahteenvuo M, et al. Growth factor therapy and autologous lymph node transfer in lymphedema. Circulation. 2011;123:613–20.
Hadamitzky C, et al. Aligned nanofibrillar collagen scaffolds: guiding lymphangiogenesis for treatment of acquired lymphedema. Biomaterials. 2016;102:259–67.
Huang NF, et al. The modulation of endothelial cell morphology, function, and survival using anisotropic nanofibrillar collagen scaffolds. Biomaterials. 2013;34:4038–47.
Badger C, et al. Benzo-pyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database System Rev. 2004; 2:CD003140.
Rockson SG. Diagnosis and management of lymphatic vascular disease. J Am Coll Cardiol. 2008;52:799–806.
Tabibiazar R, et al. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med. 2006;3:e254.
Tabibiazar R, et al. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med. 2006;3:e254.
Nakamura K, et al. Anti-inflammatory pharmacotherapy with ketoprofen ameliorates experimental lymphatic vascular insufficiency in mice. PloS One. 2009;4:e8380.
Tian W, et al. Leukotriene B4 antagonism ameliorates experimental lymphedema. Sci Translat Med. 2017; 9(389):eaal3920.
Whelan TJ, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307–16.
Olson JA Jr, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol. 2008;26:3530–5.
Wilke LG, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491–500.
Lucci A, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657–63.
Galimberti V, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305.
Choi YH, Seo KS. Correlation among bioimpedance analysis, sonographic and circumferential measurement in assessment of breast cancer-related arm lymphedema. Lymphology. 2014;47:123–33.
Devoogdt N, et al. Postoperative evolution of thickness and echogenicity of cutis and subcutis of patients with and without breast cancer-related lymphedema. Lymphat Res Biol. 2014;12:23–31.
Hwang JH, et al. A new soft tissue volume measurement strategy using ultrasonography. Lymphat Res Biol. 2014;12:89–94.
Johnson KC, et al. Ultrasound and clinical measures for lymphedema. Lymphat Res Biol. 2016;14:8–17.
Mayrovitz HN, Weingrad DN, Lopez L. Patterns of temporal changes in tissue dielectric constant as indices of localized skin water changes in women treated for breast cancer: a pilot study. Lymphat Res Biol. 2015;13:20–32.
Mellor RH, et al. Dual-frequency ultrasound examination of skin and subcutis thickness in breast cancer-related lymphedema. Breast J. 2004;10:496–503.
Suehiro K, et al. Skin and subcutaneous tissue ultrasonography features in breast cancer-related lymphedema. Ann Vasc Dis. 2016;9:312–6.